37943-54-7

Usage

Uses

Used in Pharmaceutical Development:
8-Benzyl-1,4-dioxa-8-azaspiro[4.5]decane is utilized as a lead compound in pharmaceutical development due to its unique spirocyclic structure and the presence of a benzyl group. 8-benzyl-1,4-dioxa-8-azaspiro[4.5]decane serves as a foundation for the design of new drugs, targeting various therapeutic areas based on its potential biological activities.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 8-benzyl-1,4-dioxa-8-azaspiro[4.5]decane is employed as a subject of study for its potential to contribute to the understanding of structure-activity relationships. Its unique features make it valuable for investigating the effects of spirocyclic structures on drug efficacy and selectivity.
Used in Drug Design:
8-Benzyl-1,4-dioxa-8-azaspiro[4.5]decane is used as a structural motif in drug design to enhance the stability and bioavailability of new pharmaceutical agents. Its incorporation into drug molecules can potentially improve their pharmacokinetic and pharmacodynamic properties, leading to more effective treatments.
Used in Chemical Synthesis:
8-Benzyl-1,4-dioxa-8-azaspiro[4.5]decane serves as a key intermediate in the synthesis of more complex organic compounds and pharmaceuticals. Its unique spirocyclic framework can be further modified or used as a building block to create novel molecules with specific therapeutic targets.
Used in Biochemical Studies:
In biochemical research, 8-benzyl-1,4-dioxa-8-azaspiro[4.5]decane may be used as a tool to probe the interactions between small molecules and biological macromolecules, such as proteins or nucleic acids. Understanding these interactions can provide insights into the molecular mechanisms of action and help in the development of targeted therapies.

InChI:InChI=1/C14H19NO2/c1-2-4-13(5-3-1)12-15-8-6-14(7-9-15)16-10-11-17-14/h1-5H,6-12H2

Upstream product

• 20821-52-7 1-benzyl-4-piperidone hydrochloride 
• 107-21-1 ethylene glycol 
• 100-39-0 benzyl bromide 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 1233656-18-2 C₁₆H₁₉O₄P 
• 84157-05-1 phenyl(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)methanone 
• 98-88-4 benzoyl chloride 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 51787-77-0 1,4-dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid ethyl ester 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 40110-55-2 ethyl 2-(1-benzylpiperidine-4-ylidene)acetate 
• 76876-70-5 N-benzyl-4-(2-hydroxyethyl)piperidine 
• 174643-75-5 4-[2-(Diphenylmethoxy)ethyl]-1-(phenylmethyl)piperidine 
• 40256-34-6 2-((1-benzyl-4-methylpiperidin-4-yl)oxy)ethanol 
• 40256-36-8 2-(1-benzyl-4-propyl-4-piperidyloxy)-ethanol 
• 40256-25-5 N-Benzyl-4-(2'-hydroxyethoxy)-piperidine 
• 40256-35-7 2-(1-benzyl-4-ethyl-4-piperidyloxy)-ethanol 
• 51787-82-7 8-[4,4-bis-(4-fluoro-phenyl)-butyl]-1,4-dioxa-8-aza-spiro[4.5]decane 
• 51787-84-9 4-(1,4-dioxa-8-azaspiro<4.5>dec-8-yl)-4'-fluorobutyrophenone 
• 131184-64-0 1-<1-(2-benzodioxanylmethyl)-4-piperidyl>amino-3-(1-naphthoxy)-2-propanol 

Relevant academic research and scientific papers

IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.

PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

Mild and selective Et2Zn-catalyzed reduction of tertiary amides under Hydrosilylation conditions

Diethylzinc (Et2Zn) can be used as an efficient and chemoselective catalyst for the reduction of tertiary amides under mild reaction conditions employing cost-effective polymeric silane (PMHS) as the hydride source. Crucial for the catalytic activity was the addition of a substoichiometric amount of lithium chloride to the reaction mixture. A series of amides containing different additional functional groups were reduced to their corresponding amines, and the products were isolated in good-to-excellent yields.

ROMP-derived oligomeric phosphates for application in facile benzylation

The development of new ROMP-based oligomeric benzyl phosphates (OBP n) is reported for use as soluble, stable benzylating reagents. These oligomeric reagents are readily synthesized from commercially available materials and conveniently polymerized and purified in a one-pot process, affording bench-stable, pure white, free-flowing solids on multigram scale. Utilization in benzylation reactions with a variety of nucleophiles is reported.

Structure-activity relationship studies of novel 4-[2-[bis(4- fluorophenyl)methoxy]ethyl]-1-(3-phenylpropyl)piperidine analogs: Synthesis and biological evaluation at the dopamine and serotonin transporter sites

Several analogs of the potent dopamine (DA) transporter ligand 4-[2- [bis(4-fluorophenyl)-methoxy]ethyl]-1-(3-phenylpropyl)piperidine, 1b, were made and biologically evaluated for their binding at the DA and serotonin (5HT) transporters in rat striatal membranes. Different alkyl chain lengths and substitutions were introduced in these molecules to generate an optimum activity and selectivity for the DA transporter. In general, unsubstituted and fluoro-substituted compounds were the most active and selective for the DA transporter. The compound 4-[2(diphenylmethoxy)ethyl]-1-benzylpiperidine, 9a, showed high potency and was the most selective for the DA transporter (5HT/DA = 49) in this series of compounds. Some of these novel analogs were found to be more selective in binding at the DA transporter than the original GBR 12909 molecule, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3- phenylpropyl)piperidine.

SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF NEW 7-SUBSTITUTED FLUOROQUINOLONES

Reaction of substitued 3-carboxyquinolone derivatives IIIa, IIIb, IIIc, and IV with 4-pyridone ethylene ketal in pyridine afforded corresponding 7-substituted derivatives VIa, VIb, VIc, and VIIa, respectively.Acidic deprotecion of these compounds yielded respective oxo derivatives VId, VIe, VIf, and VIIb which were converted to their oximes If, Ig, Ih, and IIb.

Synthesis of the new α- and β-adrenergic antagonist 1-[1-(2-benzodioxanylmethyl)-4-piperidyl]amino-3-(1-naphthoxy)-2- propanol

The synthesis and in vitro α- and β-adrenergic blocking potency of 1-[1-(2-benzodiaxanylmethyl)-4-piperidyl]amino-3-(1-naphthoxy)-2- propanol (I) are described. Thus, N-benzyl-4piperidone was protected and debenzylated to the carbamate (V), which upon alkaline hydrolysis and acylation gave benzodioxanic amide (IX). Reduction of the amide group, deprotection of the ketone function of (X), and reductive amination gave the 4-aminopiperidine (XIII), which was finally condensed with the appropriate epoxide to yield the aminopropanol (I). Compound (I) is formally derived from a combination of piperoxan (II) and propranolol (III), and was approximately 10 times less potent than each one of these drugs, as an α- and β-adrenergic blocker respectively.